{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:32:01Z","timestamp":1793215921341,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LB Pharmaceuticals Inc."},{"name":"LB Pharma, Paid Consultant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Regulation of dopamine activity has important clinical consequences, most notably in schizophrenia. LB-102, <jats:italic>N-<\/jats:italic>methyl amisulpride, is a novel dopamine D<jats:sub>2\/3<\/jats:sub>\/5-HT<jats:sub>7<\/jats:sub> inhibitor being developed as a treatment for schizophrenia and other psychiatric disorders. The characteristic that is common to all current antipsychotics is their engagement of D<jats:sub>2<\/jats:sub> dopamine receptors. The goal of this study was to measure the dopamine receptor occupancy of orally administered LB-102 at three different doses (50, 75, and 100\u2009mg as single doses and 50 and 100\u2009mg as multiple doses) and at different timepoints in healthy volunteers using positron emission tomography (PET) with <jats:sup>11<\/jats:sup>C raclopride as a radiotracer. Results of this study (NCT04588129) showed that steady-state once daily oral dosing of 50\u2009mg LB-102 afforded striatal dopamine occupancy (RO) in the desired 60\u201380% range consistently over the course of 24\u2009h. Contrary to the often observed relationship between RO vs plasma concentrations, maximum dopamine RO significantly lagged maximum plasma concentration and showed little variability under steady state conditions. A similar phenomenon has recently been reported with a non-racemic version of amisulpride [1]. LB-102 was generally safe and well-tolerated at all doses. Results of this study were used to inform dosing in a subsequent Phase 2 clinical study in schizophrenia patients.<\/jats:p>","DOI":"10.1038\/s41386-024-01951-x","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:03:44Z","timestamp":1729094624000},"page":"372-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8367","authenticated-orcid":false,"given":"Dean F.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh B.","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Caito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Grattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Hixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-6129","authenticated-orcid":false,"given":"Ginger","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lessie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Prensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4159-0778","authenticated-orcid":false,"given":"Andrew R.","family":"Vaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"1951_CR1","doi-asserted-by":"crossref","unstructured":"Hopkins SC, Toongsuwan S, Corriveau TJ, Watanabe T, Tsushima Y, Asada T, et al. Discovery and model-informed drug development of a controlled-release formulation of nonracemic amisulpride that reduces plasma exposure but achieves pharmacodynamic bioequivalence in the brain. Clin Pharmacol Ther. 2024;116:460\u201370.","DOI":"10.1002\/cpt.3311"},{"key":"1951_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","volume":"2","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Stahl SS. The dopamine hypothesis of schizophrenia- A review. Schizophr Bull 1976;2:19\u201376.","journal-title":"Schizophr Bull"},{"key":"1951_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pnpbp.2013.10.003","volume":"48","author":"MV Seeman","year":"2014","unstructured":"Seeman MV, Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction?. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:155\u201360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"1951_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/schbul\/sbu220","volume":"41","author":"S Wulff","year":"2015","unstructured":"Wulff S, Hageman Pinborg L, Svarer, Thorbj\u00f8rn Jensen L, \u00d8degaard Nielsen M, Allerup P, et al. Striatal D2\/3 binding potential values in drug-na\u00efve first-episode schizophrenia patients correlate with treatment outcome. Schizophrenia Bull. 2015;41:1143\u201352.","journal-title":"Schizophrenia Bull"},{"key":"1951_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.schres.2012.06.027","volume":"140","author":"Z Yilmaz","year":"2012","unstructured":"Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, et al. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. Schizophrenia Res. 2012;140:214\u201320.","journal-title":"Schizophrenia Res"},{"key":"1951_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12248-010-9247-4","volume":"13","author":"R De Greef","year":"2011","unstructured":"De Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13:121\u201330.","journal-title":"AAPS J"},{"key":"1951_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AA Abbas","year":"2009","unstructured":"Abbas AA, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL, et al. Potent 5-Ht7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119\u201328.","journal-title":"Psychopharmacology"},{"key":"1951_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","volume":"206","author":"PB Hedlund","year":"2009","unstructured":"Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Pyschopharmacology. 2009;206:345\u201354.","journal-title":"Pyschopharmacology"},{"key":"1951_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neuropharm.2004.11.015","volume":"48","author":"LJ Bristow","year":"2005","unstructured":"Bristow LJ, Hadingham K, Rosahl TW, Beer MS, Stanton JA, Bromidge F, et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48:492\u2013502.","journal-title":"Neuropharmacology"},{"key":"1951_CR10","doi-asserted-by":"crossref","unstructured":"Loebel A, Koblan KS, Tsai J, Deng L, Fava M Kent J, et al. Randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate the efficacy and safety of non-racemic amisulpride (41994199) for the treatment of bipolar I depression. J Affective Disorders. 2022; 296549-558.","DOI":"10.1016\/j.jad.2021.09.109"},{"key":"1951_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0327(96)00103-6","volume":"43","author":"Y Lecrubier","year":"1997","unstructured":"Lecrubier Y, Boyer R, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43:95\u2013105.","journal-title":"J Affect Disord"},{"key":"1951_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0165-0327(97)00139-0","volume":"48","author":"E Smeraldi","year":"1998","unstructured":"Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission A double-blind, comparative study. J Affect Disord. 1998;48:47\u201356.","journal-title":"J Affect Disord"},{"key":"1951_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/BF02245616","volume":"124","author":"JL Martinot","year":"1996","unstructured":"Martinot JL, Paill\u00e8re-Martinot ML, Poirier MF, Dao-Castellana MH, Loc\u2019h C, Mazi\u00e8re B. In vivo characteristics of dopamine D 2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 1996;124:158\u2013158.","journal-title":"Psychopharmacology"},{"key":"1951_CR14","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.1021\/acsomega.9b02144","volume":"4","author":"V Grattan","year":"2019","unstructured":"Grattan V, Vaino AR, Prensky Z, Hixon MS. Antipsychotic benzamides amisulpride and LB-102 display polypharmacy as racemates, S enantiomers engage receptors D2 and D3, while R Enantiomers Engage 5-HT7. ACS Omega. 2019;4:14151\u20134.","journal-title":"ACS Omega"},{"key":"1951_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"14","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;14:939\u201351.","journal-title":"Lancet."},{"key":"1951_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/schbul\/sbn005","volume":"35","author":"J Rabinowitz","year":"2008","unstructured":"Rabinowitz J, Levine SZ, Narkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophrenia Bull. 2008;35:775\u20138.","journal-title":"Schizophrenia Bull"},{"key":"1951_CR17","doi-asserted-by":"publisher","first-page":"S922","DOI":"10.1016\/S0924-977X(17)31639-5","volume":"27","author":"JC Neill","year":"2017","unstructured":"Neill JC, Grayson B, Cadinu D, Beconi M, Grattan V, Hixon MS, et al. Pre-clinical evaluation of two novel benzamides LB-102 and 103 for the treatment of Schizophrenia. Eur Neuropsychopharmacol. 2017;27:S922\u2013S923.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1951_CR18","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00213-022-06185-7","volume":"239","author":"L Biernat","year":"2022","unstructured":"Biernat L, Grattan VT, Hixon MS, Prensky Z, Vaino AR. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2\/3\/5-HT7 inhibitor. Psychopharmacology. 2022;239:3009\u201318.","journal-title":"Psychopharmacology."},{"key":"1951_CR19","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","volume":"232","author":"RE Davis","year":"2015","unstructured":"Davis RE, Vanover KE, Zhou Y, Brasic JR, Buevara M, Bisuna B, et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology. 2015;232:2863\u201372.","journal-title":"Psychopharmacology."},{"key":"1951_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","volume":"44","author":"KE Vanover","year":"2019","unstructured":"Vanover KE, Davis RE, Zhou Y, Ye W, Brasic JR, Gapasin L, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology. 2019;44:598\u2013605.","journal-title":"Neuropsychopharmacology."},{"key":"1951_CR21","unstructured":"PMOD Version 3.9. PMOD: https:\/\/www.pmod.com."},{"key":"1951_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224\u201347.","journal-title":"Hum Brain Mapp."},{"key":"1951_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroimageI. 1996;4:153\u20138.","journal-title":"NeuroimageI"},{"key":"1951_CR24","doi-asserted-by":"crossref","unstructured":"Logan J, Fowler KS, Volkow NS, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-[C-11]-methyl- (-)-Cocaine PET. studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137.","DOI":"10.1038\/jcbfm.1990.127"},{"key":"1951_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1951_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/01.WCB.0000085441.37552.CA","volume":"23","author":"M Ichise","year":"2003","unstructured":"Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C] DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096\u2013112.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1951_CR27","unstructured":"https:\/\/github.com\/IDAETeam\/The-_Integrative-Data-Analysis-Environment-for-Brain-PET."},{"key":"1951_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","volume":"33","author":"B Fischl","year":"2002","unstructured":"Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341\u201355.","journal-title":"Neuron"},{"key":"1951_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00228-020-03021-9","volume":"77","author":"DF Wong","year":"2021","unstructured":"Wong DF, Raufinia A, Bricmont P, Brasic JR, McQuade RD, Forbes RA, et al. An open-label, positron emission tomography study of the striatal D2\/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol. 2021;77:717\u201325.","journal-title":"Eur J Clin Pharmacol"},{"key":"1951_CR30","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.euroneuro.2019.09.156","volume":"29","author":"A Vaino","year":"2019","unstructured":"Vaino A, Grattan V, Prensky Z, Hixon M. Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic. Eur Neuropsychopharmacol. 2019;29:S87\u2013S88.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1951_CR31","doi-asserted-by":"publisher","first-page":"22m14544","DOI":"10.4088\/JCP.22m14544","volume":"84","author":"JM Kane","year":"2023","unstructured":"Kane JM, Mychaskiw MA, Lim S, Suett M, Tian M, Rubio JM. Treatment journey from diagnosis to the successful implementation of a long-acting injectable antipsychotic agent in young adults with schizophrenia. J Clin Psychiatry. 2023;84:22m14544.","journal-title":"J Clin Psychiatry"},{"key":"1951_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/S1461145703003912","volume":"7","author":"A Takano","year":"2004","unstructured":"Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol. 2004;7:19\u201326.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1951_CR33","first-page":"178","volume":"96","author":"BJ Henderson","year":"2015","unstructured":"Henderson BJ, Lester HA. Inside-out neuropharmacology of nicotinic drugs. Neuropsychopharmacology. 2015;96:178\u201393.","journal-title":"Neuropsychopharmacology."}],"updated-by":[{"DOI":"10.1038\/s41386-025-02056-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01951-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:01:20Z","timestamp":1738317680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1951"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-01951-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41386-025-02056-9","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41386-025-02056-9","URL":"https:\/\/doi.org\/10.1038\/s41386-025-02056-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VTG and MSH are consultants to, and shareholders of, LB Pharmaceuticals. AE, ZP, and ARV are employees and shareholders of LB Pharmaceuticals. DFW has WUSTL contracts with Eisai, Anavex, LB Pharma, Roche, Intracellular Technologies and is a paid consultant to Engrail Therapeutics and he and his CNAMI lab are supported by NIH (NIMH, NIDA, NIA, NIAAA) and the McDonnell Center for Systems Neuroscience at Washington University. GN has WUSTL contracts with COMPASS pathways, Usona Institute and Alkermes, Inc.; she has served as a paid consultant for Carelon, Novartis and Alkermes, Inc.; she and her staff in the Healthy Mind Lab are supported by research funding from the NIMH, the Health Resources and Services Administration (HRSA), the Patient Centered Outcomes Research Institute (PCORI); the Sidney R. Baer Jr. Foundation and the Barnes Jewish Hospital Foundation; the Institute for Clinical Translational Sciences, the Taylor Family Institute for Innovative Psychiatric Research, the Mallinckrodt Institute of Radiology and the McDonnell Center for Systems Neuroscience at Washington University. Gerhard Gr\u00fcnder is a paid consultant to LB Pharmaceuticals. GBC, NC, EL, HK, LT, IV, THS declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}